<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843945</url>
  </required_header>
  <id_info>
    <org_study_id>CT004</org_study_id>
    <nct_id>NCT02843945</nct_id>
  </id_info>
  <brief_title>Initial Feasibility Study to Treat Pancreatic Cancer With a Planar LDR Source</brief_title>
  <official_title>Initial Feasibility Study to Evaluate the Safety and Efficacy of the Permanently Implantable LDR CivaSheet® in Combination With External Beam Radiation in the Treatment of Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CivaTech Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CivaTech Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Initial study to evaluate local control and the preferred method of attachment of the
      CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor
      removal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Feasibility study to determine the safety and efficacy of a new brachytherapy
      device that provides unidirectional radiation which utilizes active components
      (Palladium-103) of standard devices in a novel configuration.This pilot study may benefit
      pancreatic cancer patients by reducing the radiation dose to adjacent critical structures,
      while giving a therapeutic dose to diseased tissue, such as at a surgical margin. The
      appropriate dose and local control rate will be recorded the primary endpoint in order to
      provide an efficacy assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose escalation Phase I followed by a feasibility trial in Phase II</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of CivaSheet Radiation Treatement</measure>
    <time_frame>1 Year</time_frame>
    <description>Patients will be monitored for any adverse radiation toxicity effects from the CivaSheet device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of CivaSheet Radiation Treatment</measure>
    <time_frame>1 Year</time_frame>
    <description>Patients will be monitored for one year to determine the local cancer recurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity of patients following surgery and radiation</measure>
    <time_frame>2 Year</time_frame>
    <description>2 year survival rates for patients post surgery and CivaSheet radiation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Radiation Dosimetry Calculation</measure>
    <time_frame>1 Month</time_frame>
    <description>Post procedure 3D treatment planning will be performed to determine if the radiation dose delivered was satisfactory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>1 Month</time_frame>
    <description>Length of hospital stay will be monitored to determine if CivaSheet radiation treatment alters the typical length of hospital stay for patients after surgery.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Directional Brachytherapy Source Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directonal nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LDR Planar Directional Brachytherapy Source</intervention_name>
    <description>The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.</description>
    <arm_group_label>Directional Brachytherapy Source Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Subject signed inform consent

               -  Age &gt; 18 years

               -  Not pregnant or breast feeding

               -  Patient capable of undergoing anesthesia

               -  Patient selected to undergo Whipple procedure or distal pancreatectomy

               -  Patient does not have metastatic disease

               -  Patients will have close margins

               -  No prior radiation therapy to the region for separate cancer

               -  Confirmed diagnosis of borderline resectable or locally advanced pancreatic
                  adenocarcinoma

               -  Patient Received neoadjuvant chemoradiation (4-10 weeks prior to surgery)

               -  Induction chemotherapy was administered with any combination of the following
                  agents:

               -  Gemcitabine + nb-paclitaxel

               -  FOLFIRINOX

               -  Neoadjuvant Chemordiation was administered as IMRT or 3DCRT wPreoperative
                  External beam dose (NCCN)

               -  50.4 Gy (1.8 Gy per fraction) with concurrent gemcitabine, capecitabine, or
                  infusional 5-fluorouracil

        Exclusion Criteria:

          -  Not surgical candidate

          -  Any other invasive cancer in the past 5 years, except basal cell skin

          -  An IRE candidate (IRE is Percutaneous irreversible electroporation)

          -  Recurrent or previously resected tumors

          -  Documented History of Alcoholism and or drug abuse

          -  Participant in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carra Castagnero</last_name>
    <phone>919-314-5515</phone>
    <email>clinical@civatechoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristy Perez, PhD</last_name>
    <phone>9193145515</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rush University Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Miller</last_name>
      <phone>312-563-2008</phone>
      <email>Zachary_Miller@Rush.edu</email>
    </contact>
    <investigator>
      <last_name>Dian Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Novak</last_name>
      <phone>215-728-3512</phone>
      <email>Andrew.Novak@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Josh Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daeryl Williamson</last_name>
      <phone>804-628-2334</phone>
      <email>johnsondl4@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Emma Fields, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brachytherapy</keyword>
  <keyword>CivaSheet</keyword>
  <keyword>CivaTech</keyword>
  <keyword>whipple</keyword>
  <keyword>radiation</keyword>
  <keyword>borderline resectable</keyword>
  <keyword>locally advanced</keyword>
  <keyword>Pd-103</keyword>
  <keyword>intraoperative radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

